Binnopharm Group, a Russian pharmaceutical company, has submitted 50 applications for trademark registration in Asia and the CIS in 2024. These applications, filed through the World Intellectual Property Organization (WIPO), cover 23 countries, including China, Southeast Asian countries and the CIS, according to the manufacturer’s press service.
«Currently, six of the company’s over-the-counter drugs have received legal protection following successful examinations in China and Southeast Asian markets. <…> In 2024, the number of trademark registration applications filed increased fourfold compared to the previous year», — the company said in its statement.
This surge in intellectual property activity is aimed at expanding the company’s supply geography and launching new products, CEO Rustem Muratov stated. Binnopharm’s products are currently available in 15 countries, including those in the CIS and Asia, while the company also develops local representative offices in the CIS countries, China, and Vietnam.
TASS also reports that Binnopharm’s export sales rose by 12% in January-February 2025 compared to the same period last year, outpacing the market average of 8%. The most significant growth was seen in Uzbekistan, where sales increased by 203%. Sales in Armenia rose by 56%, while in Kyrgyzstan, Binnopharm secured the fifth position in the market, achieving a share of 2.9%. The company has also obtained 17 registration certificates for drugs in Russia and neighboring countries, including Turkmenistan, Tajikistan, and Mongolia, focusing on medicines for infectious, cardiovascular, and gastrointestinal diseases.
Earlier, Binnopharm announced the filing of an application for the registration of its flagship drug, Neobutin, in China in late November 2024. This makes Neobutin one of the first Russian medicines undergoing registration in China.
